Literature DB >> 17189231

Intensifying daunorubicin in induction for patients with core binding factor leukemia.

Nobuaki Dobashi, Yuko Yamaguchi, Osamu Asai, Shingo Yano, Hiroshi Osawa, Yuichi Yahagi, Yutaka Takei, Katsuki Sugiyama, Takeshi Saito, Noriko Usui.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17189231     DOI： 10.1532/IJH97.06138

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

1.  Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.

Authors:  J C Byrd; R K Dodge; A Carroll; M R Baer; C Edwards; J Stamberg; M Qumsiyeh; J O Moore; R J Mayer; F Davey; C A Schiffer; C D Bloomfield
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

2.  Role of daunorubicin in the induction therapy for adult acute myeloid leukemia.

Authors:  N Usui; N Dobashi; T Kobayashi; S Yano; N Maki; O Asai; T Saito; Y Yamaguchi; H Watanabe; A Kato; A Ogihara; M Katori; M Nagamine; Y Takei; H Yamazaki; S Funakoshi; N Tajima; M Ogawa; Y Kuraishi
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

3.  Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.

Authors:  R F Schlenk; A Benner; J Krauter; T Büchner; C Sauerland; G Ehninger; M Schaich; B Mohr; D Niederwieser; R Krahl; R Pasold; K Döhner; A Ganser; H Döhner; G Heil
Journal:  J Clin Oncol       Date:  2004-08-02       Impact factor: 44.544

4.  Intensified daunorubicin in induction therapy and autologous peripheral blood stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute myeloid leukemia.

Authors:  Noriko Usui; Nobuaki Dobashi; Osamu Asai; Shingo Yano; Yuichi Yahagi; Takeshi Saito; Yuko Yamaguchi; Kinuyo Kasama; Yutaka Okawa; Naohiro Sekiguchi; Yutaka Takei; Katsuki Sugiyama; Yoji Ogasawara; Hiroko Ohtsubo; Ken Kaito; Masayuki Kobayashi
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.490

5.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Authors:  D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

6.  Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

Authors:  John C Byrd; Amy S Ruppert; Krzysztof Mrózek; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Judith Stamberg; Prasad R K Koduru; Joseph O Moore; Robert J Mayer; Frederick R Davey; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

7.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Authors:  C D Bloomfield; D Lawrence; J C Byrd; A Carroll; M J Pettenati; R Tantravahi; S R Patil; F R Davey; D T Berg; C A Schiffer; D C Arthur; R J Mayer
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.